Atyr pharma inc (LIFE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues:
Total revenues

8,065

-

184

94

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

3,616

3,590

3,799

3,314

3,345

3,549

4,202

6,484

6,150

5,310

7,133

8,420

9,204

9,144

10,395

11,307

12,000

12,670

7,739

7,502

6,593

4,341

4,410

3,638

4,388

General and administrative

2,590

2,516

1,883

2,421

2,532

2,414

2,475

3,476

4,070

5,890

3,694

3,487

4,007

3,383

3,470

4,126

4,115

3,813

3,574

3,396

2,329

1,689

1,821

1,725

1,542

Total operating expenses

6,206

6,106

5,682

5,735

5,877

5,963

6,677

9,960

10,220

11,200

10,827

11,907

13,211

12,527

13,865

15,433

16,115

16,483

11,313

10,898

8,922

6,030

6,231

5,363

5,930

Income (loss) from operations

1,859

-5,962

-5,498

-5,641

-5,877

-5,963

-6,677

-9,960

-10,220

-11,200

-10,827

-11,907

-13,211

-12,527

-13,865

-15,433

-16,115

-16,483

-11,313

-10,898

-8,922

-6,030

-6,231

-5,363

-5,930

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-363

-231

-194

-59

46

50

28

-39

-16

-182

-149

-8

-400

-225

-163

Total other expense, net

-107

-171

-147

-207

-260

-359

-437

-452

-447

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Consolidated net income (loss)

1,752

-

-

-

-6,137

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interest in Pangu BioPharma Limited

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) attributable to aTyr Pharma, Inc.

1,753

-5,973

-5,645

-5,848

-6,137

-6,322

-7,114

-10,412

-10,667

-11,474

-11,190

-12,138

-13,405

-12,566

-13,819

-15,383

-16,087

-16,493

-11,329

-11,080

-9,071

-6,038

-6,631

-5,588

-6,093

Basic net income (loss) per share

0.25

-

-

-

-2.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing basic net income (loss) per share

6,881

-

-

-

2,418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss) per share

0.25

-

-

-

-2.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing diluted net income (loss) per share

6,884

-

-

-

2,418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

-

0

139

139

138

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,329

-11,095

-

-6,038

-6,770

-5,727

-6,231

Net loss per share attributable to common stockholders, basic and diluted

-

-

-1.47

-1.80

-

-7.54

-3.33

-4.88

-0.36

-24.63

-0.43

-0.51

-0.56

-0.53

-0.58

-0.65

-0.68

7.58

-0.48

-0.74

-9.39

-6.95

-8.02

-6.85

-7.87

Weighted average common stock shares outstanding, basic and diluted

-

-

3,846

3,244

-

-25,496

2,134

2,133

29,795

-65,987

25,818

23,810

23,739

23,723

23,696

23,672

23,631

23,904

23,581

14,901

966

865

843

836

791

License Revenues [Member]
Total revenues

8,065

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration Revenue [Member]
Total revenues

-

-

184

94

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-